作者
Dang The Hung, Suhaib Ghula, Jeza Muhamad Abdul Aziz, Abdelrahman M Makram, Gehad Mohamed Tawfik, Ali Ahmed-Fouad Abozaid, Rohan Andrew Pancharatnam, Amr Mohamed Ibrahim, Muhammad Besher Shabouk, Morgan Turnage, Saloni Nakhare, Zahra Karmally, Basel Kouz, Tran Nhat Le, Suleiman Alhijazeen, Nguyen Quoc Phuong, Alaa Mohamed Ads, Ali Hussein Abdelaal, Nguyen Hai Nam, Tatsuo Iiyama, Kyoshi Kita, Kenji Hirayama, Nguyen Tien Huy
发表日期
2022/7/1
来源
International Journal of Infectious Diseases
卷号
120
页码范围
217-227
出版商
Elsevier
简介
Objectives
This study aimed to evaluate the efficacy and adverse events of favipiravir in patients with COVID-19.
Methods
Our protocol was registered on PROSPERO (CRD42020206305). Fourteen databases were searched until February 8th, 2021. An update search for new RCTs was done on March 2nd, 2022. Meta-analysis was done for randomized controlled trials (RCTs) and non-RCTs.
Results
Overall, 157 studies (24 RCTs, 1 non-RCT, 21 observational studies, 2 case series, and 106 case reports) were included. On hospitalized patients, in comparison to standard of care, favipiravir showed a higher rate of viral clearance at day 5 (RR = 1.60, p = 0.02), defervescence at day 3–4 (RR = 1.99, p <0.01), chest radiological improvement (RR = 1.33, p <0.01), hospital discharge at day 10–11 (RR = 1.19, p <0.01), and shorter clinical improvement time (MD = –1.18, p = 0.05). Regarding adverse events, favipiravir …
学术搜索中的文章
DT Hung, S Ghula, JMA Aziz, AM Makram, GM Tawfik… - International Journal of Infectious Diseases, 2022